A Phase 4 interventional study of Artificial intelligence (AI) decision-support tool in Breast Cancer Screening and Artificial Intelligence (AI), sponsored by Jonsson Comprehensive Cancer Center. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Jonsson Comprehensive Cancer Center · Phase 4, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Jonsson Comprehensive Cancer Center.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, this one has the largest planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 44th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 40–80 · Healthy volunteers
Jonsson Comprehensive Cancer Center · Sites in United States
Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 16 · Phase 3 2 · Phase 4 2
First in 1997; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400,000 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 42 across the 37 interventional studies, 27 across the 3 observational. Of the 30 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.
5 of the studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06387173Jonsson Comprehensive Cancer CenterRegistry of Patients Undergoing Cryoablation for Early Stage Breast Cancer | 2027-01-03 |
| NCT04297020Jonsson Comprehensive Cancer CenterBrain Health in Breast Cancer Survivors | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
| NCT05595499Jonsson Comprehensive Cancer CenterFisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | 2027-08-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in real-world U.S. settings and to assess patients' and radiologists' perspectives on AI in medicine.
The main question it aims to answer is: Does an FDA-cleared AI decision-support tool for digital tomosynthesis (DBT) improve screening outcomes in real world US clinical settings?
This trial will include all interpreting radiologists and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (University of California, Los Angeles (UCLA), University of California, San Diego (UCSD), University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period.
All screening mammograms at these facilities will be randomized to either intervention (radiologist assisted by an AI decision support tool) versus usual care (radiologist alone) to see if interpreting these mammograms with the AI tool's assistance improves patient screening outcomes.
We are targeting 400,000 screening exams across the participating health systems in this trial.
During the RCT the AI support tool will be randomized to be turned on or off (1:1) at the mammography exam level. Patients who return for screening exams in year 2 of recruitment will be randomized again (e.g., they will not retain their prior randomization). Radiologists will not be able to sort exams based on AI availability or AI scores. Randomizing by exam level will ensure that we capture a substantial number of interpretations with vs. without AI for each radiologist, allowing for quantification of the radiologist-level AI learning curve. We are not randomizing at the facility level as some radiologists interpret exams acquired at different facilities on the same day. By randomizing AI at the exam level, we will have the best ability to estimate and adjust for temporal trends in screening outcomes across individual radiologists. Randomization across large regional health systems will be managed independently at each participating site.
Our RCT randomizes screening mammography exams to be interpreted either with or without an AI decision-support tool. As a result, radiologists cannot be blinded to study arm during screening mammography interpretation. However, interpreting radiologists and facility staff (e.g., those scheduling the exams) will not know in advance which patients will be randomized to the AI tool. Randomization occurs within minutes after the breast imaging acquisition (i.e., when the mammography technologist captures the images) by an automated system that was developed by a third-party AI platform and successfully piloted at UCLA. Thus, the AI data (or lack thereof) is embedded within the mammogram before the radiologist opens the exam, preventing any option to "add AI" to an exam randomized to be interpreted without AI. Radiologists will be aware of AI availability only at the time of interpretation, as AI information will appear upon opening the exam (e.g., the AI information pops up with the exam images).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This trial will include all radiologists interpreting screening mammography and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (UCLA, UC San Diego, University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period. Individuals must meet the following eligiblity criteria.
Inclusion Criteria:
Exclusion Criteria:
1. Patients who have opted out of all research at the health system
3D screening exams randomized to this arm will be interpreted by the radiologist assisted by the AI decision-support tool (i.e., intervention).
Device: Artificial intelligence (AI) decision-support tool
3D screening exams randomized to this arm will be interpreted in accordance with standard care (i.e., interpreted by the radiologist alone, without an AI decision-support tool's assistance).
The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information). Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system.
Cancer detection rate
Number of screening exams recommended for breast biopsy (final Breast Imaging- Reporting and Data System \[BI-RADS\] assessment of 4 or 5) resulting in detected cancer, per 1,000 screening exams
Time frame: Cancer diagnosed within 90 days of positive study entry screening mammogram
Recall rate
Number of screening exams recalled for diagnostic work-up (initial BI-RADS assessment of 0, 3, 4, or 5), per 1,000 screening exams
Time frame: Through study completion, an average of 1 year
Interval cancer rate (i.e., false-negative rate)
Number of screening exams with a negative assessment (final BI-RADS assessment of 1 or 2) and breast cancer diagnosed within 1 year, per 1,000 screening exams
Time frame: Cancer diagnosed within 365 days of a negative study entry screening mammogram
False positive recall rate
Proportion of screening exams recalled for additional imaging (final BI-RADS assessment of 1, 2, or 3), with no breast cancer diagnosed within 1 year
Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram
False positive short-interval follow-up recommendation rate
Proportion of screening exams recalled for short-interval follow-up (final BI-RADS assessment of 3) with no breast cancer diagnosed within 1 year
Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram
False positive biopsy recommendation rate
Proportion of screening exams recalled for breast biopsy (final BI-RADS assessment of 4 or 5) with no breast cancer diagnosed within 1 year
Time frame: No cancer diagnosed within 365 days of a positive study entry screening mammogram
Trust and confidence in AI
Trust and confidence in AI gathered from focus group and survey data
Time frame: Years 1,2 and Years 4,5
Efficiency metrics (only for the UCLA site)
Interpretation time required for radiologists to interpret each mammogram with versus without AI. Delivery time, using time stamp data from exam acquisition to delivery of results to patients (aka turnaround time).
Time frame: Through study completion, an average of 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — A de-identified dataset from this study will be deposited in the Patient-Centered Outcomes Data Repository (PCODR) housed at the Inter-university Consortium for Political and Social Research (ICPSR) at the University of Michigan, in compliance with PCORI's Policy on Data Management and Data Sharing.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 28 months is below that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jonsson Comprehensive Cancer Center →